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RESEARCH ARTICLE Open Access
Skating on thin ice: pragmatic prescribing
for medication refractory schizophrenia
Derek K. Tracy1,2*, Dan W. Joyce2,3, S. Neil Sarkar2,4, Maria-Jesus Mateos Fernandez2 and Sukhwinder S. Shergill2,3
Abstract
Background: Clozapine is the treatment of choice for medication refractory psychosis, but it does not benefit half
of those put on it. There are numerous studies of potential post-clozapine strategies, but little data to guide the
order of such treatment in this common clinical challenge. We describe a naturalistic observational study in 153
patients treated by a specialist psychosis service to identify optimal pharmacotherapy practice, based on outcomes.
Methods: Medication and clinical data, based on the OPCRIT tool, were examined on admission and discharge
from the national psychosis service. The primary outcome measure was the percentage change in mental state
examination symptoms between admission and discharge and the association with medication on discharge.
Exploratory analyses evaluated the specificity of individual medication effects on symptom clusters.
Results: There were fewer drugs prescribed at discharge relative to admission, suggesting an optimisation of
medication, and a doubling of the number of patients treated with clozapine. Treatment with clozapine on
discharge was associated with maximal decrease in symptoms from admission. In the group of patients that did
not respond to clozapine monotherapy, the most effective drug combinations were clozapine augmentation with
1) sodium valproate, 2) lithium, 3) amisulpride, and 4) quetiapine. There was no support for a dose–response
relationship for any drug combination.
Conclusions: Clozapine monotherapy is clearly the optimal medication in medication refractory schizophrenia and
it is possible to maximise its use. In patients unresponsive to clozapine monotherapy, augmentation with sodium
valproate, lithium, amisulpride and quetiapine, in that order, is a reasonable treatment algorithm. Reducing the
number of ineffective drugs is possible without a detrimental effect on symptoms. Exploratory data indicated that
clozapine was beneficial across a range of symptoms domains, whereas olanzapine was beneficial specifically for
hallucinations and lamotrigine for comorbid affective symptoms.
Keywords: Schizophrenia, Psychosis, Refractory, Treatment
Background
Clinical outcomes in schizophrenia are often disappoint-
ing: a third of patients are resistant to standard pharma-
cological interventions [1], fewer than one in eight
individuals fully recover [2], and data are particularly
disheartening for negative and cognitive symptoms [3].
Clozapine is the most effective antipsychotic for more
treatment naïve [4] and medication refractory patients
[5], but half will not show significant improvement on
it [6–9]. There is limited evidence for polypharmacy –
including augmentation of clozapine [10] - or above li-
censed dose use of antipsychotics, and both increase
side effects [11]. Naturalistic – or partially naturalistic -
studies such as CATIE and CUTLASS confirmed cloza-
pine’s superior efficacy (although this was not the primary
outcome for the CATIE study, and assignment to cloza-
pine in the phase II part was not randomised), and the ab-
sence of any significant effect on negative or cognitive
symptoms; but were able to offer little pragmatic guidance
for post-clozapine treatment. Guidelines [12–14] provide
extensive lists of potential post-clozapine strategies, in-
cluding the use of other drug classes including mood-
stabilisers and anti-depressants - but recognise the frank
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inability to select between them. Clinicians are thus faced
with an unenviable but relatively common challenge of
treating patients resistant to first and second line treat-
ments in the absence of robust data to further guide
them [15].
Three critical issues occur in the “post-clozapine” lit-
erature: study methodologies; heterogeneity of psychosis
outcomes; and a medication accumulation bias. The re-
search gold standard remains the double-blinded rando-
mised controlled trial (RCT), but trial participants are
less representative of clinical populations with respect of
co-morbidity, insight and capacity to consent, and antic-
ipated drug class effects are underpowered to elicit the
well-recognised subpopulations of full-, partial-, and
non-responders. Trials typically evaluate a single com-
pound against placebo, with fewer head-to-head trials,
and very few data on adjunct treatments. It is perhaps
not surprising that there is little agreement about clin-
ical, pharmacological or demographic factors associated
with outcomes [16]. Clinical opinion with respect to in-
dividual patient presentations – that is specific symptom
profiles and local prescribing culture - often dictates
choice and duration of treatment, with wide geograph-
ical variation [17], often contrary to evidence [18]. Fi-
nally patients typically accrue increasing medications,
with management often comprising addition of new
medication, with existing (or previously added) ones sel-
dom discontinued for fear of causing destabilisation.
However remission often does not occur and such poly-
pharmacy is more likely to become the rule rather than
the exception.
Aim
We describe a naturalistic study of outcomes in 153
treatment refractory inpatients on a specialist tertiary
psychosis service, the National Psychosis Service (NPS)
at the Maudsley and Bethlem Royal Hospitals, London,
UK. The admission criteria to the service are analogous
to those of the United Kingdom’s Department of Health
definition and guidelines [19] for specialist services
(Table 1). Such criteria give broad descriptions of how a
treatment refractory illness might manifest, for example
through high symptom burden and/or significant impact
on social functioning, as well as illustrate anticipated
prior pharmacological and psychological interventions
and durations. However they act as guidance, and can be
superseded by the clinical judgement of the referring or
assessing psychiatrist; for example, whilst it would ordin-
arily be anticipated that a referred patient would have
had previous psychological intervention(s), it is recog-
nised that there can be circumstances wherein this
would have been untenable; furthermore “high symptom
burden” and “significant impact on functioning” are not
further quantified, but designed to allow a clinical
discretion in interpretation. We have previously reported
upon the nature of, and the clinical and psychosocial im-
provements demonstrated by, this service [20], but
briefly, the National Psychosis Unit is a 23 bedded unit,
staffed with Consultant Psychiatrists, junior doctors, spe-
cialist clinical psychologists, mental health nurses, a
social worker and occupational therapy staff members.
Staff work closely within an interdisciplinary setting with
weekly in-depth multiprofessional ward reviews of each
patient. All patients are offered specialist psychological
input, family therapy, and a range of occupational ther-
apy. It is sited within the Bethlem Royal Hospital, South
London, in extensive landscaped grounds, with access to
swimming, a gym, and a range of occupational therapy
activities. There is ready access to specialised pharmacy,
haematology, and cardiology input, and it has a close as-
sociation with the Psychosis Clinical Academic Group at
the Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, enabling very close links with
field-leading research. Herein we set out to evaluate:
a) the feasibility of rationalising pharmacological treat-
ment; b) to identify the most common medications
prescribed on discharge (as a posited index of their
optimal tolerated treatment); c) exploratory analysis
of medication(s) associated with overall outcomes and
specific symptom domains.
Methods
The methodology of data collection is described in our
earlier work [20], but in brief, clinical notes of patients
admitted to the NPS between 2001 and 2007 were col-
lated and retrospective analysed using the OPCRIT sys-
tem. Ethical approval for such retrospective analysis of
patient case notes was approved by the Research and
Development office of South London and Maudsley
NHS Foundation Trust, UK. Of the 182 patients
Table 1 Criteria for referral to the NPS, based on Department of
Health Guidelines (DoH, 2009)
Criteria for complex and/or refractory disorder services
Generic complex/refractory criteria Specific to a psychosis centre
Diagnostic uncertainty hampering
treatment
Failure to respond adequately
(or tolerate) two antipsychotics
(at least one atypical)
Persistently high symptom burden
Significant impact on functioning Attempted adequate trial of
clozapine, usually for a minimum
of 6–9 monthsPersisting (>2 years) pattern of
incapacity despite appropriate
treatment
Multiple comorbidities increasing
likelihood of chronicity
Appropriate psychological
therapies such as cognitive
behavioural therapy and family
interventions should have been
attempted
Need for specialised treatments,
e.g. TMS
Inpatient stay >6-12 months
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admitted during this time, 153 case notes (86 male, 67
female) were deemed to contain sufficient information
to allow reliable assessment of clinical information: all
patients with such information were included in the
study, and no other inclusion or exclusion criteria were
utilised. Mean participant age at the point of admission
was 33 (s.d. = 10.9); mean duration of admission was
254 days (s.d. = 169). All participants met ICD-10 cri-
teria for a primary diagnosis of schizophrenia, which was
by definition of admission to this tertiary unit, consid-
ered considerably treatment refractory; 36 had a comor-
bid personality disorder; 36 had a lifetime history (and
24 at the point of admission) of alcohol dependency or
harmful use; 49 had a lifetime history (and 37 at the
point of admission) of cannabis dependency or harmful
use; and 31 a lifetime history (23 at the point of
admission) of dependency or harmful use of other sub-
stances. These categories are not exclusive, with some
individuals having more than one co-morbidity. The
only exclusion criterion for patient admission to the
National Psychosis Unit is if they cannot be physically
managed by staff due to risk of significant agitation or
violence.
The OPCRIT is a reliable and validated tool [21] utilis-
ing an inventory of psychopathological symptoms,
demographics, and disease course variables that are
scored, with algorithms for clinical diagnosis [22]. The
notes on admission to, and discharge from, the NPS
were assessed to yield OPCRIT mental state examination
(MSE) severity scores for each time point across 5
domains: affective symptoms, abnormal perceptions, ab-
normal beliefs, speech and thought disorders, and ap-
pearance and behaviour. Demographic information was
collated for all participants; and medications, including
dose, on admission and discharge, were recorded.
The primary measures of outcome were change in
mental state examination (MSE) symptom severity
measured as the sum of the 5 OPCRIT mental state
variables. Each symptom domain score is ordinal (with
zero indicating an absence of those symptoms and
higher values indicating increasing symptom severity)
with maximum values as follows: affective symptoms
(maximum score = 58), abnormal perception (12), abnor-
mal belief (41), speech and thought disorder (13), and ap-
pearance and behaviour (24); resulting in a maximum
summed symptom severity of 148. The primary outcome
was the percentage change in total 5-domain MSE symp-
tom score at admission and discharge (for example, if the
total score at admission is 95, and at discharge 55, this
represents a percentage improvement of 42 %). We also
performed analyses on this primary outcome for cloza-
pine monotherapy, and clozapine augmented with the
two most frequently prescribed (in our sample) antipsy-
chotics (quetiapine, amisulpride) and mood stabilisers
(lithium, valproate). For these analyses, a simple linear
regression was used to study the effect of each drug, dose
and interactions between drugs/dose on the primary
outcome. Pre-processing and data quality checking were
performed using MATLAB 2013a. Tabulated data for
each analysis was then exported for graphing using the R
statistical package with ggplot2 libraries.
For the exploratory analysis of potential drug effects
on specific symptom domains we evaluated if the six
most commonly prescribed drugs - on which we had
enough data to model – produced changes in OPCRIT
outcomes, which we defined categorically as: 1, worse
that average improvement from admission to discharge,
where average was defined as the median change for all
patients during this time; 2, average improvement during
this time; 3, better than average improvement. Patients
who scored worse than the median - IQR (interquartile
range) get assigned outcome 1 for that mental state
outcome (e.g. speech and thought); those who scored
median +/− IQR got assigned 2; and those who outper-
formed and scored over the median + IQR got outcome
3. In this subanalysis each patient therefore had an or-
dinal, categorical score (valued at either 1, 2 or 3) in
the five outcome domains (the OPCRIT domains relat-
ing to mental state). Conventional multiple regression
analysis can only model univariate or continuous out-
comes, whereas we aimed to explore the relationship
between multiple outcomes and multiple drug/drug
combinations. To proceed, we constructed five separate
ordinal probit regression models, one for each of the
mental state categorical outcomes with the same drug
combinations as predictors. This effectively represents
five sub-analyses on the same predictors but with different
outcomes, there is a risk of Type II error, where a
significant association between drug combinations (i.e.
regression coefficients with p values less than 0.05) is
found purely by chance because of the number of sub-
analyses conducted. To counter this, the fitted regres-
sion coefficients for each of the five ordinal probit
regressions were tabulated together in descending rank
order of their p-values. These augmented regression
coefficients were then subjected to false-discovery rate
(FDR) corrections using the Benjamini and Hochberg
method to control the Type II error rate. We then re-
port only associations where regression coefficients
survived FDR correction at the q < 0.2 level appropriate
for exploratory analyses.
From the small subset of significant results, we then
transformed the regression coefficients to probabilities
of being in the worse, average or better than average cat-
egories for each drug combination in each of the five
mental state domains. The advantage of this method is
that it captures associations between drug combinations
and changes over the mental state domains similarly to
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multivariate pattern classification methods, while retain-
ing the ability to draw inferences about effect sizes in an
interpretable fashion (e.g. by extracting regression coeffi-
cients that quantify the strength and direction of the
association with mental state domains).
Missing data
Of 153 records, 11 patients had one missing drug dose
value for medications on discharge and one patient was
missing 2 dose values. In total, 3.5 % (145 individual
values from a total of 4131) of the demographics data
had missing values. There was no systematic relationship
between these missing values; they were treated as missing-
at-random and non-parametric imputation by k-nearest
neighbours was used to impute missing values.
Results
1. The prescribing data at discharge.
Table 2 gives details of medication at admission and
discharge; 47 patients were treated with clozapine
(median dose 450 mg) on admission, increasing to 90 on
discharge (412.5 mg). Of the 47 admitted on clozapine,
41 remained on clozapine at discharge; thus 49 patients
were newly commenced on this drug during admission.
The next most frequently prescribed medications at dis-
charge were sodium valproate (37/153, 1325 mg/day),
amisulpride (33/153, 400 mg/day), olanzapine (25/153,
20 mg/day), lithium (21/153, 800 mg/day), quetiapine
(21, 600 mg/day) and lamotrigine (18, 200 mg/day).
Other medications prescribed in fewer than 8 individuals
were: risperidone consta, zuclopenthixol, risperidone,
carbamazepine, sulpiride, melperone, haloperidol, droperi-
dol, flupenthixol, chlorpromazine, valproic acid, pipotia-
zine, and perphenazine. These figures do not account for
polypharmacy in individual patients, and only reflect total
medications used.
Monotherapy prescribing at discharge: clozapine and
olanzapine
The most common monotherapeutic antipsychotics
at discharge were clozapine (33/153) and olanzapine
(8/153). With clozapine (median monotherapy dose
Table 2 Medications on admission to, and discharge from, the National Psychosis Service
Drug Admission Discharge
Frequency Median dose IQR Frequency Median dose IQR
Clozapine 47 450 218.8 90 412.5 275
Sodium valproate 28 1200 925 37 1325 1000
Amisulpride 20 600 600 33 400 325
Olanzapine 36 20 2.5 25 20 10
Lithium 11 800 0 21 800 200
Quetiapine 15 550 325 21 600 237.5
Lamotrigine 10 200 25 18 200 50
Risperidone consta 8 2.7 0.5 7 2.7 0.9
Zuclopenthixol 14 28.6 14.3 6 17.9 28.6
Risperidone 11 4 2 5 4 2
Carbamazepine 11 400 350 4 400 200
Droperidol 2 90 120 3 40 0
Sulpiride 7 800 800 3 800 1200
Haloperidol 8 10 0 3 10 3.8
Melperone 1 250 0 3 500 75
Flupenthixol 6 4.4 2.9 2 4.5 3
Chlorpromazine 6 175 200 2 800 0
Valproic acid 4 750 250 1 1500 0
Perphenazine 0 0 0 1 24 0
Pipotiazine 5 6 4.7 1 5.3 0
Aripiprazole 3 30 0 0 0 0
Fluphenazine 2 1.8 0 0 0 0
Trifluoperazine 1 20 0 0 0 0
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400 mg/day (IQR = 121.9 mg)) there was a median
improvement in symptoms (percentage change in total
MSE variables) of 64.6 % (IQR = 23.8 %) (see Fig. 1).
For olanzapine monotherapy (median dose 15 mg,
IQR = 5 mg) median improvement was smaller at
30.5 %, with wider variation (IQR = 56.2 %). In both
drugs there was no significant relationship between
the prescribed dose and improvement.
Clozapine co-prescribing at discharge
The most common coprescribed antipsychotics were
amisulpride and quetiapine respectively; and mood stabi-
lising agents were sodium valproate, lithium and lamo-
trigine. Table 3 summarises the outcomes and median
dose used for the different combination therapies, and
Fig. 2 illustrates the efficacy data of the four most effica-
cious combinations. For clozapine + amisulpride, the
median improvement was 53.0 % (IQR = 39.5 %). For
clozapine + quetiapine, a similar pattern was found with
median improvement of 51.0 % (IQR = 30.5 %). No
dose–response relationship or interaction was deter-
mined for any combination. With sodium valproate
(median improvement 62.5 % (IQR = 21.1 %)) an appar-
ent trend in the data is driven by an outlier (visible on
the bottom left), and when this is removed, there is no
significant dose–response effect or interaction be-
tween drug doses and response. Of note, a majority
of patients (15) responded with total daily valproate
doses in the range 1000-2000 mg. For the 16 individuals
on combinations of clozapine + lithium, the median im-
provement was 56.9 % (IQR = 36.8 %) and again, there
was no significant dose–response or interaction effect
(with the caveat that serum lithium levels were not avail-
able and only total daily dose was measured) but median
clozapine doses were lower than other augmentation
strategies. Of the 14 patients on clozapine + lamotrigine,
a median improvement of 43.7 % (IQR = 32.05) was dem-
onstrated. No dose–response or interaction effects were
statistically significant.
Non-clozapine combination therapy at discharge
Two ‘non-clozapine’ combinations, olanzapine + valproate
(8 patients) and quetiapine + valproate (6 patients), oc-
curred sufficiently commonly to allow outcome ana-
lyses. With the former, the median improvement was
substantially lower at 15.4 % (IQR = 31.8 %), with: a
trend toward lower doses of olanzapine and better out-
comes (but no statistically significant dose–response in-
teractions); no evidence that doses of olanzapine
greater than 20 mg are beneficial (median = 22.5 mg,
IQR = 22.5 mg); but wide variation in valproate doses
(median = 1600 mg, IQR =1150 mg). Six individuals
were on the quetiapine + valproate combination, and there
was a median improvement of 33.0 % (IQR = 27.3 %) and
again, no significant dose–response/interaction effects.
The median quetiapine dose was 700 mg (IQR = 350 mg)
with a median sodium valproate dose of 1675 mg (IQR
825 mg). Table 4 charts final describing choices against
patient demographic factors.
2. Exploratory analyses of medication effects on
specific symptom subdomains
Table 5 shows the results of the multivariate analyses
of medication combinations and change in mental
state domain categories. From this, the general trend
of polypharmacy having worse outcomes is replicated,
and clozapine monotherapy is again associated with
(at worst) being a member of the average improve-
ment category on each mental state variable, and at
Fig. 1 Outcome with Clozapine Monotherapy, with black filled circles each representing a single patient. The blue line is the linear regression
trend line, with the dark grey area illustrating the 95 % confidence interval
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best abnormal belief, perception and speech and thought
domains show improvement in the above average cat-
egory. Clozapine + quetiapine as dual therapy appears as-
sociated with worse than average outcomes (which likely
reflects the principle of poorer outcomes in polypharmacy
than a deleterious combination of medications). A similar
trend is shown for clozapine + lamotrigine. Finally,
quetiapine + valproate combined confer group-average
improvement on appearance and behaviour.
The treatment protocol directs treatment to disabling
symptoms, agnostic to categorical (ICD, DSM) disease
category and therefore, we did not code schizoaffective
patients separately from, for example, paranoid schizo-
phrenia. The characteristics of schizoaffective patients
compared with schizophrenia in terms of demographics
and comorbidity has recently been documented by Pagel
et al. [23]. In their meta-analysis, they compared 2684
people with a schizoaffective diagnoses, against 10814
patients diagnosed as having schizophrenia and showed
that the schizoaffective group contained a higher propor-
tion of females (52 %), a younger mean onset of illness
of 23.3 (standard deviation +/− 3.8 years) with higher
Fig. 2 Clozapine co-prescribing with the most efficacious agents. Filled circles each represent a single patient, with the dark to light blue gradient
representing lower to higher clozapine doses. The blue line is the linear regression trend line, whilst the dark grey area represents the 95 %
confidence interval. Data are shown for co-prescribing with sodium valproate (top left), lithium (top right), amisulpride (bottom left), and
quetiapine (bottom right)
Table 3 Clozapine co-prescribing with antipsychotics and mood stabilisers (ranked in descending order of percentage median
improvement change on MSE symptom severity scores)
Augmentation Patients Median clozapine
dose (mg)
Clozapine interquartile
range (mg)
Median co-prescribed
dose (mg)
Co-prescribed dose
interquartile range (mg)
Median
improvement %
Improvement
IQR %
Sodium valproate 22 550.0 225.0 1500 800.0 62.5 21.1
Lithium 16 375.0 375.0 800 100.0 56.9 36.8
Amisulpride 26 500.0 237.5 300 200.0 53.0 39.5
Quetiapine 13 550.0 159.4 400 212.5 51.0 30.5
Lamotrigine 14 337.5 262.5 200 37.5 43.7 32.0
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ratings of both psychotic and affective symptoms. It is
therefore important and informative to examine the pro-
portions of patients with a significant affective compo-
nent (as compared to disorganised thought and speech,
abnormal belief and perception) in our treatment refrac-
tory sample. Given all patients in our sample had high
psychotic symptom loads, we further divided our data
on the basis of affective symptoms as follows. The distri-
bution of admission OPCRIT mental state variables sig-
nificantly deviated from normality, so we computed the
non-parametric Tukey five-number summary [24] yield-
ing the median and upper-hinge which, in our sample,
correspond to the 50th (median) and 75th percentile of
the distribution of affective symptom load of the
OPCRIT. We then analysed the demographics of the
subsample with the highest affective symptom load, i.e.
those with affective symptom load greater than 75th per-
centile/upper-hinge and compare with those below the
75th percentile. We found that 37/153 patients had
affective symptom load greater than the 75th percentile.
The median age of onset was 32 (IQR = 16) and 31.5
(IQR = 15.25) in the high and low affective symptom
group respectively. In terms of gender proportions, in
the high symptom load, 46 % were male and 54 % female,
consistent with Pagel et al. [23]. In the lower affective
symptom group, the proportions were 57 % male and
44 % female. We then summed symptom load on psych-
otic symptoms of speech and thought disorder, abnormal
perception and belief for the high affective symptom
group and compared them to the lower affective symptom
group. A Kolmogorov-Smirnov test confirmed that the
total psychotic symptom load differs between the high
affective compared to the low affective symptom group
(D = 0.419, p < 0.001) with the high affective symptom
group having higher median summed psychotic symptom
load of 29 (IQR = 15) compared to the low affective group
with median 19.5 (IQR = 16.3). In summary, when com-
pared with the findings of Pagel et al. [23], we found 37 /
153 patients had similar profiles to schizoaffective patients
(versus schizophrenia without affective symptoms) with
the exception that in our sample, the median age of onset
was similar between the two groups.
Discussion
The optimal management of treatment refractory schizo-
phrenia poses a significant personal, social and economic
challenge, and there is a dearth of evidence to support
treatment beyond clozapine monotherapy. We herein re-
port the results of a naturalistic study of 153 patients on
a tertiary psychosis unit. No specific treatment algorithm
was utilised, as the aim was to describe ‘real-world’ pre-
scribing patterns that altered in accordance to patient
response rather than study design, which might capture
a wider and more representative cohort of refractory pa-
tients (including many with significant histories of sub-
stance misuse and Axis II disorders); and that we might
utilise clinical outcomes as one additional element to
guide prescribing. Patients are typically discharged from
the NPS when they are at their most stable, and we ac-
cepted a model that that discharge medication repre-
sented their optimal treatment to inform further future
treatment protocols.
Table 5 Exploratory multivariate analyses of medication on change in mental state domains
Appearance and behaviour Abnormal belief Abnormal perception Affect Speech and thought
Clozapine monotherapy 0.0012 0.0004 0.0080 0.0260 0.0031
Clozapine & quetiapine 0.0086 0.0267 - - -
Clozapine & lamotrigine - - - - 0.0136
Quetiapine & valproate 0.0389 - - - -
Values indicate the p-values of the drug combination as predictor for change in categorical mental state variable at discharge (only those surviving FDR correction
at the q = 0.20 level are shown). Bold values indicate medication (combination) associations with mental state domain where improvement above the group average
was found (i.e. patients on this combination would be more likely to be in the above average category for improvement). Italicised values show the same information
but where the highest probability was for the “average” change category. Underlined values show where the medication (combination) was associated with a worse
than average change in that mental state domain
Table 4 Final prescribing patterns charted against patient variables, including age, sex, a positive family history of a psychotic illness (FHx),
a concomitant personality disorder (PD), alcohol, cannabis, or other illicit drug use
Rx: clozapine Age median (IQR) Sex (M/F) FHx PD Alcohol Cannabis Other substances
Monotherapy 27 (16) 23/13 5 13 11 13 10
+ Quetiapine 37 (12) 8/5 2 7 2 4 4
+ Amisulpiride 31 (7) 16/10 4 5 5 7 8
+ Lithium 30 (7) 8/8 1 4 2 3 2
+ Valproate 33 (7) 10/12 5 5 7 11 9
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Rational prescribing in medication refractory individ-
uals would maximise the use of clozapine, and remove
any medication without clear benefit. Clozapine use al-
most doubled from admission, with just over a third on
monotherapy; and in those few patients intolerant or un-
willing to comply with clozapine, the only other mono-
therapeutic treatment of note was olanzapine (n = 8). At
discharge, there were 9 different drugs being used by 5
or more patients (excluding clozapine), while the analo-
gous figure at admission was 16, suggesting a rationalisa-
tion and reduction in the range of non-effective drugs
accrued in these patients. Interestingly, there was a de-
crease in the use of depot antipsychotic medication from
29 to 13 at discharge that may reflect the patients trans-
ferred to clozapine. 38/153 patients with medication re-
fractory illness were discharged from the NPS on
monotherapy, compared with 18 on monotherapy on ad-
mission, and the pattern was still of significant clinical
improvement. Rationalisation of medication load, with-
out clinical destabilisation of patients’ mental states, thus
appeared to be an achievable aim.
Unsurprisingly co-prescribing with clozapine was far
more common than other non-clozapine combinations.
If our assumption is correct that the discharge medica-
tion represents individuals’ optimum prescribing, these
combinations would be a proxy marker for efficacy and
were likely to be associated with positive clinical benefit.
We examined the extent of improvement in mental state
parameters as a function of discharge medication. Cloza-
pine effected the greatest improvements in OPCRIT
markers, with a median symptom improvement of
64.6 % (IQR = 23.8 %). After clozapine monotherapy
the greatest median improvement was seen with the
addition of the mood stabilisers sodium valproate
(median improvement 62.5 %) and lithium (56.9 %)
respectively, with the former having the narrowest
improvement IQR of any added drug. Following this the
next most efficacious additions were the antipsychotics
amisulpride (53 %) and quetiapine (51 %), though the
absolute difference in median improvements from the
mood stabilisers was not large. There were far fewer
‘non-clozapine’ combinations, and the only ones with
sufficient numbers to meaningfully analyse contained
the mood stabiliser sodium valproate and an anti-
psychotic (olanzapine and quetiapine), with very limited
improvements in mental state relative to the clozapine
combinations.
Overall there was no evidence for dose–response in
any drug or combination of drugs. There were increased
median plasma clozapine levels in the combination ther-
apy relative to clozapine monotherapy. However, this is
likely to be an artefact of the treatment regimes used on
the unit, where the policy is to: aim for plasma levels of
0.35 mg/l in the first instance; to increase the dose to
levels of 0.50 mg/l if there is an inadequate response;
and if there is still insufficient benefit to augment with
another medication.
The exploratory analysis of the individual drug effects
on specific symptom domains demonstrated the super-
iority of clozapine in three domains (speech and thought;
abnormal beliefs; and appearance and behaviour), and,
with olanzapine, showing the largest effect in “abnormal
perception”; supporting the research data on clozapine
treatment of medication refractory psychosis. There was
a notable potential beneficial effect of treatment with
lamotrigine on patients with an affective symptoms clus-
ter, although this did not match the overall effectiveness
of clozapine combination treatment with other mood
stabilisers.
Caveats with our naturalistic study include that this
was an exploratory analysis in a selected sample, in the
absence of a control group and any blinding of assess-
ments. As such it cannot be regarded as evidence based
as would occur within the context of a Randomised
Controlled Trial. A limitation is that it leaves un-
answered the question of whether the apparent advan-
tages of some treatment strategies were dictated by the
intervention, or if it was the illness state the governed
the choice of intervention. Table 4 charts individuals’
demographic data against prescribing choice, but partici-
pant numbers mean that firm conclusions cannot be
reached on this important issue. However to go beyond
descriptive to inferential analyses would have required
either combinatorially large, multisubgroup analysis
using linear/generalised models, or the development of a
complete model of proposed statistical relationships
(with hypothesised dependencies between these variables)
for the 90+ OPCRIT variables (predictors and outcomes).
The latter, more elegant and complete, option represents
our group’s ongoing research, but the methodology has yet
to fully mature, and is beyond the scope of this paper on
pragmatic prescribing.
The OPCRIT is a reliable tool, but factorial validity
does not confer construct validity, and factor analyses
of the OPCRIT do not necessarily support neo-
Kraepelinian assumptions about diagnostic categories.
However, the value of OPCRIT is its mobility between
categorical and nomothetic dimensions, and OPCRIT
has been validated insofar as when the multidimen-
sional data are parsed by algorithms for categorical
diagnosis, there is concordance between clinician-
assigned diagnostic categories, ICD-10 and DSM. An
advantage to use of OPCRIT is that the mental state
domains offer a symptom load score which is agnostic
to specific diagnostic category or sub-category (e.g.
paranoid versus hebephrenic schizophrenia) and treat-
ment refractoriness. Future work might appropriately
attempt to replicate these findings utilising other
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outcome measures, not least with more functionally
meaningful tools assessed in real-world settings be-
yond the inpatient ward. Such work would better
align with individuals’ typical goals within a recovery
model beyond symptom reduction.
Retrospective note analysis is also open to challenge
[25] including through inadvertent biases in those col-
lecting the data. Our data was rated by two psychiatrists
trained in the use of OPCRIT, and a test-retest on a ran-
dom sample of ten note sets showed good inter-rater re-
liability [20]. Further, in the unit assessed, as is the case
in most UK inpatient wards, much of the documentation
is carried out by junior doctors who change every six
months: in view of this and the inconsistent use of clin-
ical scales over the time period it was considered that
the only valid and reliable way to obtain clinical infor-
mation was thus through the use of an operationalised
system such as OPCRIT. Adherence is a critical factor to
consider in medication refractory patients, and the lit-
erature on this topic is disheartening [26]. Many will
suboptimally adhere, which may adversely affect their re-
covery, though there is a very large range of behaviour
and outcomes covered by the construct of 'adherence'.
Adherence to treatment does not form part of the expli-
cit referral criteria or guidelines, and it is expected that
referring clinicians will have considered and, where rele-
vant, tried to manage this issue. Inpatient units will have
better opportunities to monitor adherence, and this fact
might have affected our outcomes; adherence was not
measured before or after treatment, and rates of ad-
herence during inpatient admission are not reported.
However, referrers would have had access to local,
non-specialised, inpatient units for admission and
monitoring of adherence had this been considered a
critical factor. There is considerable variation in the
use of long acting injectable (LAI or ‘depot’) medica-
tion geographically and between individual services;
it could be argued that fewer than expected individ-
uals with medication refractory illnesses were on this
treatment modality at the time of referral.
These data do not take into account the psychological,
occupational therapeutic, and nursing care provided for
patients on this unit, and furthermore the provision and
nature of these services on a tertiary unit might not be
reflective of wider practice and staff availability. The
National Psychosis Unit is undoubtedly an enriched en-
vironment with highly trained and motivated staff with
specialist skills in psychosis management, and ready
access to rapid interdisciplinary care and treatment.
Finally, the nature of our data collection meant that
we could not ascertain if any medication changes
were made to reduce or avoid drug side-effects or
risks, which is a potential biasing factor when inter-
preting these data.
Conclusions
In summary, our data show that medication can be opti-
mised in a chronic medication refractory sample of pa-
tients with schizophrenia; and that this is associated
with significant clinical improvement in specific symp-
tom domains. Reduction in the range of medication used
did not result in a destabilisation in mental state, but
was associated with positive outcomes. The general prin-
ciples to be drawn from the results suggest primary use
of clozapine therapy where possible in medication re-
fractory schizophrenia. Research [27] has demonstrated
a mean delay of over four years before clozapine is com-
menced, and whilst there are many reasons why this
might occur, our results reinforce the need to actively
target and overcome obstacles to clozapine treatment in
medication refractory populations. These would include
rechallenging a patient after a “red result”, liaising with
colleagues in cardiology and haematology to monitor
and treat in the many cases with comorbid illness, either
iatrogenic or extant conditions; and aggressively treating
any side effects such as sedation, hyper-salivation, and
tachycardia. Careful identification and management of
comorbid symptoms such as OCD and mood disorders
is also necessary – with regular monitoring of these target
symptoms – allied to a clear plan for discontinuing any
medication that does not benefit the target symptoms.
Given the caveats of all observational studies, our data
suggests that if clozapine monotherapy is ineffective,
that augmentation with sodium valproate is the most
efficacious option, followed by augmentation with ami-
sulpride, lithium, quetiapine, and then lamotrigine. The
last of these, lamotrigine, whilst proving the least effica-
cious in combination with clozapine, is noteworthy for
demonstrating superior efficacy in managing affective
symptoms.
Abbreviations
MSE: Mental state examination; OCD: Obsessive compulsive disorder.
Competing interests
All authors work or have worked on the unit evaluated. Derek Tracy has
received honoraria for educational talks from Lilly UK, Roche UK and Janssen
UK. Sukhwinder Shergill has received grant support from clinical trials from
GlaxoSmithKline, Roche, Abbvie and Envivo, and has served as consultant,
scientific advisor and had speaking engagements for Sunovion, Roche and
Dainippon Sumitomo Pharma.
Authors’ contributions
SSS conceived and designed the project, and was involved in the writing of
the paper. SNS and MJM were involved in data collection and study design.
DKT and DWJ were involved in data analysis and the writing of the paper.
All authors read and approved the final manuscript.
Authors’ information
Derek Tracy is a Consultant Psychiatrist and Associate Clinical Director at
Oxleas NHS Foundation Trust, London, UK, and a researcher at the Cognition,
Schizophrenia and Imaging (CSI) laboratory, the Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, UK.
Tracy et al. BMC Psychiatry  (2015) 15:174 Page 9 of 10
Dan W Joyce is a Doctor at South London and Maudsley NHS Foundation
Trust, London, UK; and a post-doctoral researcher at the CSI lab, King’s College
London, UK.
S Neil Sarkar is a Consultant Psychiatrist at Central and North West London
NHS Foundation Trust, UK.
Maria-Jesus Mateos is a researcher at the CSI lab, King’s College London, UK.
Sukhwinder S Shergill is a Professor of Psychiatry and Systems Neuroscience
at the Institute of Psychiatry, Psychology and Neuroscience, King’s College
London, UK; and an honorary Consultant Psychiatrist at South London and
Maudsley NHS Foundation Trust, UK.
Acknowledgements
This work was partly supported by the NIHR Biomedical Research Centre at
the Maudsley Hospital.
The authors wish to thank the following individuals who helped with the
initial data collection and/or study concept: Natasza Nalesnik, Gurbinder
Dhillon, Juliana Onwumere, Anne-Marye Prins, Karen Schepman, Tracy Collier,
Thomas P. White, Anita Patel, Fiona Gaughran, L. Camilo Zapata, Amber Appleton,
Poppy Elmhirst, Laura Bottwood, Sarah Elsabagh, Ben Robinson.
The authors are grateful to the reviewers for their insightful critiquing of our
work, which considerably enhanced the end product.
Author details
1Oxleas NHS Foundation Trust, Green Parks House, Orpington, Kent, BR6 8NY,
London, UK. 2Cognition, Schizophrenia & Imaging Laboratory, Department of
Psychosis Studies, the Institute of Psychiatry, King’s College London, London,
UK. 3South London and Maudsley NHS Foundation Trust, London, UK.
4Central and North West London NHS Foundation Trust, London, UK.
Received: 30 October 2014 Accepted: 14 July 2015
References
1. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for
biological treatment of schizophrenia, part 2: update 2012 on the long-term
treatment of schizophrenia and management of antipsychotic-induced side
effects. World J Biol Psychiatry. 2013;14(1):2–44.
2. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A
systematic review and meta-analysis of recovery in schizophrenia. Schizophr
Bull. 2013;39(6):1296–306.
3. Rowe AR, Mercer L, Casetti V, Sendt K-V, Giaroli G, Shergill SS, et al.
Dementia praecox redux: a systematic review of the nicotinic receptor
as a target for cognitive symptoms of schizophrenia. J
Psychopharmacol. 2015;29(2):197–211.
4. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al.
Comparative efficacy and tolerability of 15 antipsychotic drugs in
schizophrenia: a multiple-treatments meta-analysis. Lancet.
2013;382(9896):951–62.
5. Chakos M, Lieberman J, Hoffman E, Bradford D, Schumann G. Effectiveness
of second-generation antipsychotics in patients with treatment-resistant
schizophrenia: a review and meta-analysis of randomized trials. Am J
Psychiatry. 2001;158(4):518–26.
6. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic
medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.
7. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW,
et al. Clozapine and haloperidol in moderately refractory
schizophrenia: a 6-month randomized and double-blind comparison.
Arch Gen Psychiatry. 2001;58(10):965–72.
8. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A,
et al. Clinical effects of clozapine in chronic schizophrenia: response to
treatment and predictors of outcome. Am J Psychiatry.
1994;151(12):1744–52.
9. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh B, et al.
World Psychiatric Association Pharmacopsychiatry Section statement on
comparative effectiveness of antipsychotics in the treatment of
schizophrenia. Schizophr Res. 2008;100(1–3):20–38.
10. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a
second antipsychotic - a meta-analysis. Acta Psychiatr Scand.
2012;125(1):15–24.
11. Tracy DK, Sendt K-V, Shergill SS. Antipsychotic polypharmacy: still dirty, but
hardly a secret. A systematic review and clinical guide. Current
Psychopharmacology. 2013;2(2):143–71.
12. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for
Biological Treatment of Schizophrenia, part 1: update 2012 on the acute
treatment of schizophrenia and the management of treatment
resistance. World J Biol Psychiatry. 2012;13(5):318–78.
13. NICE, Core interventions in the treatment and management of
schizophrenia in primary and secondary care (update), 2009, London, UK:
National Institute for Health and Care Excellence.
14. Taylor D, Paton C, Kapur S. Prescribing Guidelines in Psychiatry.
11 ed, ed. D. Taylor, C. Paton, and S. Kapur. 2012, London, UK:
Wiley-Blackwell
15. Tracy DK, Shergill SS. Treatment-Refractory Schizophrenia: definition and
assessment. In: Gaughran F, Buckley PF, editors. Treatment Refractory
Schizophrenia: a clinical conundrum. Berlin: Springer; 2014.
16. Harrison GHopper K, Craig T, Laska E, Siegel C, Wanderling J, et al.
Recovery from psychotic illness: a 15- and 25-year international
follow-up study. Br J Psychiatry. 2001;178:506–17.
17. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines
and prescribing trends. BMC Psychiatry. 2014;14:102.
18. Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on
prescribing practices: an
analysis of data from a large midwestern state. J Clin Psychiatry.
2012;73(4):498–503.
19. DoH, NHS Specialised Services. Definition no 22. Specialised mental health
services (all ages). London, UK: D.o. Health; 2009.
20. Sarkar SN, Tracy DK, Fernandez M-JM, Nalesnik N, Dhillon G, Onwumere J, et
al. Unheard voices: outcomes of tertiary care for treatment-refractory
psychosis. The Psychiatric Bulletin, 2014; 38:71-74.
21. Brittain PJ, Stahl D, Rucker J, Kawadler J, Schumann G. A review of the
reliability and validity of OPCRIT in relation to its use for the routine clinical
assessment of mental health patients. Int J Methods Psychiatr Res.
2013;22(2):110–37.
22. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational
criteria in studies of psychotic illness. Development and reliability of the
OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764–70.
23. Pagel T, Baldessarini RJ, Franklin J, Baethge C. Characteristics of patients
diagnosed with schizoaffective disorder compared with schizophrenia and
bipolar disorder. Bipolar Disord. 2013;15(3):229–39.
24. Tukey JW. Exploratory Data Analysis. 1977, New York, USA: Pearson.
25. Mihalopoulos C, McGorry P, Roberts S, McFarlane C. The procedural validity
of retrospective case note diagnosis. Aust N Z J Psychiatry. 2000;34(1):154–9.
26. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors
influencing adherence to antipsychotic medication in schizophrenia-
spectrum disorders. Psychiatry Res. 2015;225(1–2):14–30.
27. Howes OD, Verqunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to
treatment guidelines in clinical practice: study of antipsychotic treatment
prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481–5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tracy et al. BMC Psychiatry  (2015) 15:174 Page 10 of 10
